Jazz Pharmaceuticals, Inc.

Pharmaceutical Preparations

JAZZMixed9 of 10 basics passed

$218.42

-1.81%

Market cap $14.2B

$218.42

-1.81%

Market cap $14.2B

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology.

It is a $14.2B healthcare company. Revenue grew 12.6% over the last year, it keeps 20¢ of every dollar of sales as profit, and its net debt equals ~1.8 years of free cash flow. It trades at 15.1× earnings — near the lowest of its own history.

Website: jazzpharmaceuticals.com
Location: Dublin
Employees: 2 890
Sector: Healthcare
Founded: 2003

Moved -3.9% on Oct 9, 20262.5σ — unusual for this stock

Share price · 3 years

$130.34 → $218.42+67.6%

price only — dividends excluded

Key facts · TTM

Revenue: total sales; $4.60B
Profit: keeps 20¢ of every $1 sold; $941M
Free cash flow: cash left after running the business; $1.59B
Net debt: debt minus cash on hand; $2.94B
P/E: years of profit in the price; 15.1
EPS: earnings per share, TTM; $15.43
Shares: shares outstanding; 61.0M
Volatility: beta vs the market — under 1 swings less; 0.36

Revenue, last 10 years

52-week range

Low $131.16$218.42High $261.62

Today's price is 67% of the way from the year's low to its high.

P/E vs its history5y

15.1×median 19.7×

Higher than 10% of past days — near the lowest of its own history.

Valuation vs own history

P/E

15.1×

90%

P/S

3.1×

12%

EV/EBITDA

11.7×

100%

P/B

3.0×

24%

FCF yield

11.2%

33%

Share of the last ~5 years that was pricier than today (in line with its own history). Based on the daily valuation record.

Insider activity · 90 days

-$4.13Mnet selling

Purchases$0

Sales$4.13M

Insiders trading, last 14d0 buy · 2 sell

Standing in Healthcare

Size$14.2Btop 66%
Revenue growth+5%top 61%
Net margin20%top 20%
Return on equity21%top 30%
P/E15.1×top 16%

Ranked against 98 Healthcare companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Strong valuation and quality; Growth, Health and Moat lag behind.

Valuation90

P/E vs own history10th pct · 25/25
FCF yield11.2% · 25/25
P/S3.1x · 20/25
EV/EBITDA10.7x · 20/25

Growth37

Revenue CAGR8.4% · 12/25
Net income CAGRn/a · 0/25
EPS CAGR ~5Yn/a · 0/25
Fwd implied growth61.1% · 25/25

Profitability65

ROIC-4.9% · 0/25
ROE21.4% · 20/25
Net margin20.4% · 25/25
Operating margin19.5% · 20/25

Health48

Altman Z2.13 · 18/25
Current ratio1.78 · 18/25
Interest coverage-2.2x · 0/25
Net cash / debtD/A 25% · 12/25

Quality77

Piotroski F5/9 · 15/25
Beneish M-3.68 · 25/25
FCF conversion169% · 25/25
Margin stabilityσ 14.2% · 12/25

Moat25

ROIC >12% years2/10 yrs · 0/25
Median gross margin15.1% · 0/25
FCF-positive years10/10 yrs · 25/25
Worst-year net marginworst -10.7% · 0/25

How the scores work →

Experience

The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.

FY2024Financial
Best year on record
$560M net income
FY2016Financial
First recorded profitable year
$397M net income
FY2016Financial
Revenue already above $1B
$1.49B in first reported year
FY2016Financial
Positive free cash flow every year since
10-year streak
2003Founded
It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2021 would be worth ~$16 137 today — price return only

$4.3B revenue in FY2025

Revenue up 12.6% year over year

Positive free cash flow 10 years in a row

2 890 employees

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

High gross margin (88.4%)
Strongly profitable — 20.4% net margin
Revenue growing 12.6% year over year
Strong cash conversion — FCF is 34.6% of revenue
Could repay net debt from ~1.4 years of free cash flow

Watch-outs

Thin interest coverage (-2.2×)
Loss-making in 3 of the recent years

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

9 of 10 checks passed

Revenue growing — the company sells more than a year ago+12.6% YoY
Profitable — makes more than it spends$941M TTM
Profit growing — earnings are higher than last year-163.6% YoY
Generates cash — cash left after running and investing$1.59B TTM
Debt under control — could handle its obligations~1.8y of cash flow to repay
Established company — not a micro-cap — lower blow-up risk$14.2B market cap
Not printing shares — share count not ballooning — you keep your slice+7.9% shares over ~5y
Proven track record — years of profitability behind it7/10 profitable years
Financially stable — balance sheet not near distressAltman Z 2.1 — grey
Pays a dividend — returns cash to shareholdersno data
Valuation not extreme — price not wildly above earningsP/E 15.1

Peer comparisonJazz Pharmaceuticals, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
JAZZ this company	$14.2B	15.1	+12.6%	20.4%	Mixed
LLY Eli Lilly & Co.	$1.0T	41.6	+49.6%	33.5%	Solid
JNJ Johnson & Johnson	$630.9B	29.9	+8.1%	21.5%	Mixed
ABBV Abbvie Inc.	$488.5B	77.4	+10.4%	9.8%	Mixed
MRK Merck & Co., Inc.	$361.0B	113.2	+4.6%	4.8%	Mixed
UNH UNITEDHEALTH GROUP INCORPORATED (Delaware)	$340.7B	24.1	+6.5%	3.1%	Mixed
NVS Novartis AG	$273.2B	20.3	+9.6%	24.7%	Solid

Head-to-head: JAZZ vs LLY · JAZZ vs JNJ · JAZZ vs ABBV

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 7Buy 17Hold 2

Appendix · Financial records

The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.

Profit & lossRevenue $4.60B · net income $941M (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

How FY2025 revenue flows to profit

RevenueNet income

Revenue (TTM)

$4.60B

YoY 12.6%

Net income (TTM)

$941M

Margin 20.4%

Gross margin

88.4%

Operating margin

19.5%

P/E ratio

15.1

Income statement — full detail

Figures in USD billions · EPS in USD

	2020	2021	2022	2023	2024	2025
Revenue	2.4	3.1	3.7	3.8	4.1	4.3
Gross profit	0.4	0.2	-0.1	0.6	0.7	-0.4
Operating income (EBIT)	0.4	0.2	-0.1	0.6	0.7	-0.4
Net income	0.2	-0.3	-0.2	0.4	0.6	-0.4
EPS (diluted)	4.22	-5.52	-3.58	5.76	8.49	-5.84

Cash flowFree cash flow $1.59B · operating cash flow $1.66B (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

$1.59B

Margin 34.6%

Operating cash flow (TTM)

$1.66B

FCF margin

34.6%

Cash flow statement — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Operating cash flow	0.9	0.8	1.3	1.1	1.4	1.4
Capital expenditure	-0.0	-0.0	-0.0	-0.0	-0.0	-0.1
Free cash flow	0.9	0.8	1.2	1.1	1.4	1.3
FCF margin	37.4%	24.3%	34.0%	27.9%	33.4%	30.4%

Balance sheetAssets $11.7B · net debt $2.94B (FY2025)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $11.7B of assets is financed

63%

37%

Liabilities $7.34B — borrowed moneyEquity $4.32B — owners' stake

Cash vs debt

Total debt $4.33B − cash $1.39B = net debt $2.94B

Cash on hand covers 32% of debt.

Altman Z-Score

2.13

Grey zone

Debt repayment

1.4 yrs

Years of free cash flow to clear net debt

Interest coverage

-2.2x

EBIT ÷ interest expense

ROE

21.4%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Cash & equivalents	1.1	0.6	0.9	1.5	2.4	1.4
Total assets	6.5	12.3	10.8	11.4	12.0	11.7
Total liabilities	2.9	8.3	7.7	7.7	7.9	7.3
Total debt	1.8	6.0	5.7	5.1	6.1	4.3
Equity	3.7	4.0	3.1	3.7	4.1	4.3
Net debt	0.8	5.4	4.8	3.6	3.7	2.9

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of JAZZ on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $218.42 · market cap $14.2B.